Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

58.37 +0.83 (+1.44%)

Streaming Delayed Price Updated: 10:55 AM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Volume	142,399
Open	57.68
Bid (Size)	58.28 (200)
Ask (Size)	58.40 (400)
Prev. Close	57.54
Today's Range	57.44 - 58.53
52wk Range	26.74 - 63.95
Shares Outstanding	63,562,303
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

April 07, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know ↗

March 27, 2026

This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.

Via The Motley Fool

Performance

YTD	+31.2%	+31.2%
1 Month	-7.0%	-7.0%
3 Month	+38.6%	+38.6%
6 Month	+48.7%	+48.7%
1 Year	+106.8%	+106.8%

More News

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

Via The Motley Fool

XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner ↗

February 26, 2026

Via Chartmill

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

March 12, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Via Finterra

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

March 10, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

Via Finterra

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗

March 09, 2026

Via Stocktwits

Xenon Pharmaceuticals Announces Proposed Public Offering

March 09, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Top stock movements in today's session. ↗

March 09, 2026

Via Chartmill

Monday's session: top gainers and losers ↗

March 09, 2026

Via Chartmill

Gapping stocks in Monday's session ↗

March 09, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 09, 2026

Via Chartmill

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

March 09, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 08, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

From Xenon Pharmaceuticals Inc.

Via GlobeNewswire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

February 23, 2026

Via The Motley Fool

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

Via The Motley Fool

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?

Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.

What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?

Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?

The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market

What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?

The current price of Xenon Pharmaceuticals Inc. - Common Shares is 58.37

When was Xenon Pharmaceuticals Inc. - Common Shares last traded?

The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 04/09/26 10:55 AM ET

What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?

The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 3.71B

How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?

Xenon Pharmaceuticals Inc. - Common Shares has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.